Overview of 13D Filings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 21 2026
0mins
Should l Buy OFIX?
Source: Yahoo Finance
- Definition of 13D Filings: 13D filings are disclosures required to be submitted to the SEC within 10 days when an entity acquires more than 5% of any class of a company's securities, aimed at enhancing market transparency.
- Purpose of Disclosure: The primary purpose of these filings is to inform investors about the holdings of major shareholders and their potential impact on corporate governance and strategic decisions, thereby aiding market participants in making more informed investment choices.
- Compliance Requirements: Under U.S. securities law, any investor holding more than 5% must timely submit a 13D filing to ensure that all market participants have access to relevant information, thus maintaining market fairness.
- Market Impact: The disclosure of 13D filings can trigger market interest in the related companies, influencing their stock price volatility, especially when investors speculate on the intentions and future plans of major shareholders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OFIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OFIX
Wall Street analysts forecast OFIX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.070
Low
18.00
Averages
21.33
High
24.00
Current: 12.070
Low
18.00
Averages
21.33
High
24.00
About OFIX
Orthofix Medical Inc. is a global medical technology company. It offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System. Its Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. It provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Halper Sadeh LLC Investigates Orthofix Management for Potential Breaches
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of Orthofix Medical Inc. breached their fiduciary duties, which could impact corporate governance and shareholder rights significantly.
- Legal Fee Arrangement: The firm operates on a contingency fee basis, meaning shareholders are not responsible for upfront legal costs, thereby reducing financial barriers and encouraging more shareholders to seek legal recourse.
- Importance of Shareholder Participation: Involvement from shareholders can drive improvements in company policies, practices, and oversight mechanisms, enhancing transparency and accountability, which ultimately increases shareholder value and has strategic implications for corporate governance.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, demonstrating its effectiveness in protecting investor rights.
See More
Orthofix Medical Q1 2026 Earnings Call Highlights
- Stable Sales Growth: Orthofix Medical reported total global net sales of $196.4 million in Q1 2026, reflecting a 3% year-over-year increase, with U.S. sales growing by 4%, indicating improved execution and stability in the spine commercial channel.
- Strong Distributor Performance: The top 30 distributor partners achieved a 27% year-over-year net sales growth, demonstrating significant effectiveness in distributor concentration, which enhances the company's competitive position in the market.
- Optimistic Future Outlook: Management reaffirmed the full-year 2026 net sales guidance of between $850 million and $860 million, anticipating approximately 5% growth in the first half and about 6% in the second half, reflecting confidence in market demand.
- Healthy Cash Flow Position: The first quarter's pro forma non-GAAP adjusted EBITDA was $9.7 million, with total cash reaching $120.9 million, indicating strong liquidity and profitability, despite uncertainties related to potential legal settlements.
See More
Orthofix Medical Inc. Q1 Earnings Beat Expectations
- Earnings Highlights: Orthofix Medical Inc. reported a Q1 GAAP EPS of -$0.52, beating expectations by $0.16, with revenue of $196.7 million reflecting a 1.6% year-over-year increase, surpassing market expectations by $1.99 million, indicating resilience in the market.
- Full-Year Outlook: The company reaffirms its 2026 financial guidance based on Q1 performance, expecting net sales to range between $850 million and $860 million, reflecting approximately 5.5% year-over-year growth, demonstrating confidence in future performance.
- Profitability Improvement: Expected non-GAAP adjusted EBITDA is projected to be between $95 million and $98 million, representing a 70 basis point margin expansion compared to 2025, highlighting improvements in cost control and operational efficiency.
- Cash Flow Outlook: The company anticipates positive free cash flow for the full year 2026, excluding the impact of potential legal settlements, indicating a strengthening financial position supported by margin improvement initiatives.
See More
Orthofix Medical Inc. Set to Announce Q1 Earnings on May 5
- Earnings Announcement: Orthofix Medical Inc. is set to announce its Q1 earnings on May 5 before market open, with a consensus EPS estimate of -$0.29, reflecting a significant year-over-year increase of 78.5%, indicating efforts towards profitability recovery.
- Revenue Expectations: The consensus revenue estimate stands at $194.71 million, representing a modest year-over-year growth of 0.6%, suggesting the company's stability and operational continuity in the market despite limited growth.
- Historical Performance Review: Over the past year, Orthofix has beaten EPS estimates 50% of the time and revenue estimates 75% of the time, demonstrating a degree of reliability in its financial performance.
- Expectation Revisions: In the last three months, there have been no upward revisions to EPS estimates, with one downward revision, while revenue estimates faced three downward adjustments, reflecting a cautious market outlook on the company's future performance.
See More
ORTHOFIX MEDICAL INC - DISCONTINUES PRESIDENT POSITION IN GLOBAL SPINE SOLUTIONS
Company Announcement: Orthofix Medical has announced the termination of its President, who was also the Global Spine Solutions leader.
Impact on Leadership: This decision may lead to significant changes in the company's leadership structure and strategic direction within the spine solutions division.
See More
ORTHOFIX MEDICAL INC ANNOUNCES ESTIMATED NET SALES OF $196.7 MILLION FOR Q1 2026
Financial Performance: Orthofix Medical reported preliminary net sales of $196.7 million for the first quarter of 2026.
Market Position: The sales figures indicate a strong performance in the medical device market, reflecting the company's growth strategy.
Future Outlook: The company is likely to continue focusing on expanding its product offerings and market reach based on these preliminary results.
Investor Interest: The positive sales report may attract investor attention and confidence in Orthofix Medical's future prospects.
See More
Halper Sadeh LLC Investigates Orthofix Management for Potential Breaches
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of Orthofix Medical Inc. breached their fiduciary duties, which could impact corporate governance and shareholder rights significantly.
- Legal Fee Arrangement: The firm operates on a contingency fee basis, meaning shareholders are not responsible for upfront legal costs, thereby reducing financial barriers and encouraging more shareholders to seek legal recourse.
- Importance of Shareholder Participation: Involvement from shareholders can drive improvements in company policies, practices, and oversight mechanisms, enhancing transparency and accountability, which ultimately increases shareholder value and has strategic implications for corporate governance.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, demonstrating its effectiveness in protecting investor rights.
See More
Orthofix Medical Q1 2026 Earnings Call Highlights
- Stable Sales Growth: Orthofix Medical reported total global net sales of $196.4 million in Q1 2026, reflecting a 3% year-over-year increase, with U.S. sales growing by 4%, indicating improved execution and stability in the spine commercial channel.
- Strong Distributor Performance: The top 30 distributor partners achieved a 27% year-over-year net sales growth, demonstrating significant effectiveness in distributor concentration, which enhances the company's competitive position in the market.
- Optimistic Future Outlook: Management reaffirmed the full-year 2026 net sales guidance of between $850 million and $860 million, anticipating approximately 5% growth in the first half and about 6% in the second half, reflecting confidence in market demand.
- Healthy Cash Flow Position: The first quarter's pro forma non-GAAP adjusted EBITDA was $9.7 million, with total cash reaching $120.9 million, indicating strong liquidity and profitability, despite uncertainties related to potential legal settlements.
See More
Orthofix Medical Inc. Q1 Earnings Beat Expectations
- Earnings Highlights: Orthofix Medical Inc. reported a Q1 GAAP EPS of -$0.52, beating expectations by $0.16, with revenue of $196.7 million reflecting a 1.6% year-over-year increase, surpassing market expectations by $1.99 million, indicating resilience in the market.
- Full-Year Outlook: The company reaffirms its 2026 financial guidance based on Q1 performance, expecting net sales to range between $850 million and $860 million, reflecting approximately 5.5% year-over-year growth, demonstrating confidence in future performance.
- Profitability Improvement: Expected non-GAAP adjusted EBITDA is projected to be between $95 million and $98 million, representing a 70 basis point margin expansion compared to 2025, highlighting improvements in cost control and operational efficiency.
- Cash Flow Outlook: The company anticipates positive free cash flow for the full year 2026, excluding the impact of potential legal settlements, indicating a strengthening financial position supported by margin improvement initiatives.
See More
Orthofix Medical Inc. Set to Announce Q1 Earnings on May 5
- Earnings Announcement: Orthofix Medical Inc. is set to announce its Q1 earnings on May 5 before market open, with a consensus EPS estimate of -$0.29, reflecting a significant year-over-year increase of 78.5%, indicating efforts towards profitability recovery.
- Revenue Expectations: The consensus revenue estimate stands at $194.71 million, representing a modest year-over-year growth of 0.6%, suggesting the company's stability and operational continuity in the market despite limited growth.
- Historical Performance Review: Over the past year, Orthofix has beaten EPS estimates 50% of the time and revenue estimates 75% of the time, demonstrating a degree of reliability in its financial performance.
- Expectation Revisions: In the last three months, there have been no upward revisions to EPS estimates, with one downward revision, while revenue estimates faced three downward adjustments, reflecting a cautious market outlook on the company's future performance.
See More
ORTHOFIX MEDICAL INC - DISCONTINUES PRESIDENT POSITION IN GLOBAL SPINE SOLUTIONS
Company Announcement: Orthofix Medical has announced the termination of its President, who was also the Global Spine Solutions leader.
Impact on Leadership: This decision may lead to significant changes in the company's leadership structure and strategic direction within the spine solutions division.
See More
ORTHOFIX MEDICAL INC ANNOUNCES ESTIMATED NET SALES OF $196.7 MILLION FOR Q1 2026
Financial Performance: Orthofix Medical reported preliminary net sales of $196.7 million for the first quarter of 2026.
Market Position: The sales figures indicate a strong performance in the medical device market, reflecting the company's growth strategy.
Future Outlook: The company is likely to continue focusing on expanding its product offerings and market reach based on these preliminary results.
Investor Interest: The positive sales report may attract investor attention and confidence in Orthofix Medical's future prospects.
See More
